Providing investors with the
tools to make informed decisions.
Providing investors with the
tools to make informed decisions.
 Tracking 1271 U.S. listed China Stocks and Counting...
 Tracking 3167 U.S. Stocks and Counting...
Created: 01-Jan-2008

Extra Insight into some of the more controversial issues surrounding China Companies

  • Thursday, December 18, 2014, 12:48 PMmore... 
    Global Sources Lt (NASDAQ:GSOL) renewed its contract to host its highly successful trade shows at AsiaWorld-Expo (AWE) in Hong Kong in 2017 and 2018 for approximately US$23.1 million.
     
  • Thursday, December 18, 2014, 12:45 PM 
    Tier 1 Pink Kreisler Mfg Co (PINK:KRSL) announced a $3.00 dividend. 
  • Thursday, December 18, 2014, 12:44 PM 
    Tier 1 PInk Pd-Rx Pharmaceuti (PINK:PDRX) reported FY2014 (year ending June 30 2014) EPS of $1.13 vs. $0.70 in the prior year period. 
  • Wednesday, December 17, 2014, 12:26 PMmore... 
    Extendicare Inc (PINK:EXETF) announced its intention to purchase for cancelation up to 10% of the public float of its common shares over a maximum 12-month period.
  • Wednesday, December 17, 2014, 12:25 PMmore... 
    Highpower Interna (NASDAQ:HPJ) announced that Huizhou Highpower Technology Ltd., Highpower International's wholly-owned subsidiary, officially qualified for addition to Samsung's supply chain as a supplier of lithium-based battery products.
  • Tuesday, December 16, 2014, 11:00 AMmore... 
    Concord Medical S (NYSE:CCM) announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 52% equity interest in Chang'an Hospital to the owner of the 48% equity, for a total consideration of RMB 398 million (US$64.8 million or $1.44 per share).
  • Tuesday, December 16, 2014, 10:59 AMmore... 
    Lightinthebox Hol (NYSE:LITB) announced that its Board of Directors has authorized to extend its existing share repurchase program for an additional 12-month period through December 15, 2015.
  • Tuesday, December 16, 2014, 10:56 AM 
    Coding Rcm Technologies (NASDAQ:RCMT) as a GeoBargain. See our full note here
  • Friday, December 12, 2014, 09:00 AM 
    SLOT now trades as "" (OTC BB:SLOTD).
  • Thursday, December 11, 2014, 09:30 AMmore... 
    GeoBargain B- Scada Inc. (PINK:SCDA) reports preliminary 32% annual revenue increase which equates to a record $640,000 Q4 2014 following previous record results of $574,000 in Q3 2014. The company profitability is expected to decline due to increasing its investment into the company including  marketing initiative to help drive growth.  We are not overly concerned in the decrease in profitability at these stages in SCDA’s growth cycle, since achieving top line growth rate in excess of 20% is the key factor in the early stages of SaaS companies (from our experience).  The company has set a target of 25% revenue growth for the Company overall for 2014-2015.
     
  • Thursday, December 11, 2014, 09:30 AMmore... 
    GeoBargain on the radar Igi Laboratories (NYSE AMEX:IG) announced pricing of convertible notes. The Notes will be convertible at an initial conversion price of approximately $11.29 per share, which represents a conversion premium of approximately 27.0% over yesterday's closing price.  Estimated dilution from conversion translates to about 25%. IG intends to use the proceeds for general corporate purposes, including, without limitation, capital expenditures and potential future acquisitions and strategic transactions.
     
  • Thursday, December 11, 2014, 09:30 AMmore... 
    Tuniu Corporation (NASDAQ:TOUR) - rumor is Jd.com Inc. (NASDAQ:JD) might participate in TOUR's planned $100 million equity offering.
     
  • Thursday, December 11, 2014, 09:00 AM 
    AVRN now trades as Avra (OTC BB:AVRND).
  • Wednesday, December 10, 2014, 10:16 AMmore... 
    Refer to our short investment thesis on Bio-Reference Laboratories, Inc. (NASDAQ:BRLI) on Seeking Alpla: "Bio-Reference Laboratories Tested: Undisclosed Lawsuit Alleges Fraud, Ex-Employees Speak Out". 
  • Wednesday, December 10, 2014, 09:30 AMmore... 
    Momo Inc. (PINK:MOMO) (Upcoming IPO) - a mobile-based social networking platform in China is is offering 16 million American Depositary Shares (ADS) and sees pricing of $12.50 to $14.50 each.  Shares are set to begin trading tomorrow. 
     
  • Wednesday, December 10, 2014, 09:30 AMmore... 
    China Information (NASDAQ:CNIT) announced that the Company was selected by a leading advertising agency to install 10,000 cloud-based new media elevator terminals in Fujian province.
  • Wednesday, December 10, 2014, 09:30 AMmore... 
    Tuniu Corporation (NASDAQ:TOUR) announced that the Company has signed a strategic agreement with Ctrip.com International CTRP, to expand their collaboration on shared travel resources.
     
  • Wednesday, December 10, 2014, 09:30 AMmore... 
    Nq Mobile Inc. Am (NYSE:NQ) announced changes in the company’s management team and a voluntary two year share lock up by a group of the company’s largest shareholders. Current Co-CEO and Chairman of Board, Mr. Henry Yu Lin, stepped down from his position for “personal reasons unrelated to the company” and three founders, including Mr. Lin, agreed to an additional two year lock up period of their collective shares.  
     
  • Wednesday, December 10, 2014, 09:30 AMmore... 
    Forevergreen Worl (OTC BB:FVRG) - Revisiting the FVRG story as the company once again issues strong financial guidance. FVRG announced fiscal 2015 revenue guidance of $90 to 100 million, 55 to 70% growth over 2014 and net income guidance of $3.6 to $5 million (EPS of $0.17 to $0.23). In our 5/20/2013 email we mentioned that we were taking a speculative position in FVRG when the stock was trading at $0.22.  In our 10/1/2013 we mentioned that we were locking in some profits as the stock hit new 52 week high of $1.98.  On 11/21/2013 we locked in the rest of our gains as we closed out our position around $1.50.  We have stated on several occasions that we are still uncertain if this is a legitimate company or a possible pump and dump, and will continue to track the story.   We will re-kindle our due diligence efforts. 
  • Tuesday, December 9, 2014, 09:30 AMmore... 
    Soufun Holdings L (NYSE:SFUN) announced that the strategic cooperation agreements the company entered into with CTC and certain other parties on October 7, 2014 have been terminated.
more GeoAlerts...
Comming Soon
Comming Soon
Comming Soon
 
Board Tips & Tricks: (View All)
  • After you subscribe to a Board, use the boards drop down menu at top of page to see it listed in your Favorite Boards screen.
  • You can click the number in parentheses next to a username in order to see all GeoInvesting messages posts by that user.
  • In message lists, use the orange arrow at the right to expand the messages for quick reading.
  • You can direct your posts towards certain users in the "Send as Alert to User(s)" field when composing a post. The message will be forwarded to their GEO inbox and real email.
  • Categorize your posts!!! There are 10 different kinds of post types. We will all then be able to filter all message lists by post type.
  • Search the boards by stock symbol, user name, or just in general. You will be given those options when entering text in the search field.
  • Place a $ in front of symbols in your posts. The stock name and exchange will then be included. (example: $CCME) This is also helpful when tweeting the message since aggregators such as stock twits will pick it up.
ChinaResearch 07-Sep-2011 05:04 AM
Post Type: Public Public
CMED (#11844) In Response to original message: #11542 posted by mbgizmo on 10-Aug-2011 11:03 AM

Investors should use extreme caution when investing in Chinese companies listed in North America. From the information gathered and I believe CMED is another Chinese fraud which raised foreign capital by selling a growth China story. The capital is used to grossly overpay for acquisitions from oblique, often directly related counter party.

1) The due diligence investigation started from the comparison of SAIC vs. SEC reporting. As can see from below table, there is 300mm difference between their local & SEC reporting. I can’t tell why this is such a difference, but the main issues are mainly in 2007 and 2008 while they launched their “high profitable” FISH business.

Company Level (RMB)

Revenue

12/31/2006

12/31/2007

12/31/2008

12/31/2009

12/31/2010

Total Difference

CMED reported

495,580,000

794,622,000

1,112,122,000

795,978,000

787,680,000

SAIC revenue

301,145,200

789,775,884

833,725,200

1,017,073,600

714,080,000

Difference

(194,434,800)

(4,846,116)

(278,396,800)

221,095,600

(73,600,000)

(330,182,116)

Breakdown

GP

-

21,841,300.00

123,323,200.00

394,060,000.00

404,550,000.00

YDME

301,145,200.00

740,444,084.04

690,089,900.00

605,720,000.00

309,530,000.00

BBE

-

27,490,500.00

20,312,100.00

17,293,600.00

NA

GP-Only

SAIC

12/31/2006

12/31/2007

12/31/2008

12/31/2009

12/31/2010

Total

Revenue

-

21,841,300

123,323,200

394,060,000

404,550,000

943,774,500

SEC

12/31/2006

12/31/2007

12/31/2008

12/31/2009

12/31/2010

FISH (GP)

0

98,074,000

284,482,000

393,505,000

462,424,000

1,238,485,000

Difference

0

(76,232,700)

(161,158,800)

555,000

(57,874,000)

(294,710,500)

YMDE & BBE

SAIC

12/31/2006

12/31/2007

12/31/2008

12/31/2009

12/31/2010

Total

Revenue

301,145,200

767,934,584

710,402,000

623,013,600

309,530,000

2,712,025,384

SEC

12/31/2006

12/31/2007

12/31/2008

12/31/2009

12/31/2010

HIFU/ECLIA

495,580,000

696,548,000

827,640,000

402,473,000

325,256,000

2,747,497,000

Difference

(194,434,800)

71,386,584

(117,238,000)

220,540,600

(15,726,000)

(35,471,616)

2) History of Related Party Transactions: like other Chinese fraud names, CMED engaged a bunch of unclear and questionable acquisitions. These activities raise significant concerns about Management motivations.

  1. Bought original ECLIA business (2004) from the chairman for $30.2mm
  2. Bought main building from chairman for $7.8mm
  3. Sold the headline business, HIFU, to chairman for $53.5mm, received over 2.5 years
  4. Bought BBE-Ekon indirectly from Yimin, owned by ex-assistant to chairman.
  5. Bought FISH (2/07) and SPR (12/08) business from CytoTrend
    1. Chen Zhong, chief scientist post FISH acquisition files many patent applications on behalf of Cytotrend/CMED some related to SPR, before SPR is bought but after he is CMED employee. When SPR deal announced his tie to them or even potential conflict not disclosed.

a) BBE Acquisition:- CMEDannounced on 11/08/2007 that it purchased entire equity interest in Beijing Bio-Ekon Biotechnology Co., Ltd, a local Chinese firm, for $28.8mm. When I checked the SAIC filling for BBE, the local government filing shows that the entire consideration was roughly $7.5mm. So question is where did $21mm go?

Sep 2006 to Mar 13 2007 - An entity called Yimin buys up lots of individual Ekon holders on private deals. It pays RMB 49mm. Yimin is controlled by Chen Shu Jun, a 30 year old former assistant to CMED’s CEO Wu Xiaodong. Its pre-acquisition assets are comprised of a small cash balance and 2 HIFU machines. (Mr. Wu even issued a letter to confirm Yimin’s purchase of HIFU machines from YDME which used to help the SAIC registration process)

Apr 18 2007 - Clear Castle Investments Limited (BVI) buys East Crest Enterprises Limited (Hong Kong) from READY-MADE INCORPORATIONS LTD (BVI) i.e., East Crest is a clean empty shell.

May 30 2007 – Yimin sells Ekon to East Crest for RMB 53.6mm and records investment income of RMB4.85mm for FY2007.

Nov 26 2007 - CMED announced it will pay $28.8mm for BBE. It does not disclose the seller nor mention East Crest, Clear Castle, nor Yimin. The only asset it says it acquired is BBE.

Jan 08 2008 – CMED completed acquisition. In 20-F for FY ‘07 (Mar 2008) it lists only BBE as a subsidiary and announces that the seller is Finnea International Limited, with no other details. In 20-F for FY ’08 (Mar 2009) it finally also lists Clear Castle and East Crest as subsidiaries above BBE.

Conclusion – CMED “overpaid” $21mm for an asset that traded twice for $7.5mm only six months prior with one of those trades done by a potentially related party.

b) FISH & SPR acquisitions – CMED claimed it bought FISH assets from Supreme Well -> Molecular Diagnostics -> CytoTrend in Feb 2007. Paid $136.8mm plus $40mm earn out. Chen Zhong, a former Utah professor and former co-director of University of Utah cytogenetic lab, small owner and director in CytoTrend in the past and filer of many patents on its behalf, becomes CMED chief scientist. He signs a 5 year employment and non-compete agreement with CMED as a condition of acquisition. From the merger agreement (filed Sep 2007) it is clear CMED is contemplating purchasing the SPR business from CytoTrend as well (does so in Oct 2008, almost two years later). Both FISH and SPR are research businesses with no revenues prior to the acquisition.

There is possible connection between Chen Zhong and Molecular Diagnostics (MD). He used to be the chairman of CytoTrend and owned 1 share, while MD owned the balance. It is hard to believe that he was the face of the company, led the research effort but had no equity at time of sale. In the official bio, or discussion of the acquisitions, there is no mention of his relationship with CytoTrend though he used to own it, was its chairman, and filed patents on its behalf.

July 20 2007 – CMED pays $22mm as good faith money to Supreme Well for SPR.

Aug/Sep 2007 – Chen Zhong files 20 patent applications with either CMED or CytoTrend as assignee (hard to tell original since it may have been changed later). If it is CytoTrend then he is actively working for them even though they are in negotiations on SPR. If it is CMED then CMED already gets many SPR patents, even though they have not yet acquired SPR. What exactly did they acquire if they already have the IP?

Nov 19 2007 – Chen Zhong becomes CTO of CMED.

Oct 07 2008 – CMED announces SPR acquisition for $345mm, paid over one year. There is no mention of Chen Zhong’s connection to CytoTrend. They are asked on the call about the seller and all they say is that they’ve bought FISH from them before. In the press release they estimate SPR potential market size at $700mm and expect $23 to $26mm revenue in FY09. In FY10 they sold $4mm worth. In their latest presentation they estimate the market will be $250mm in five years.

3) Audit committee received a letter in 2009 alleging improper conduct of senior management in connection with asset acquisitions and sales. Contents were not disclosed. Announced after “independent investigation” completed and found no evidence.

4) The funding environment was getting worse this year after the massive Chinese frauds. CMED might find the capital markets closed to them on corporate governance concerns according to Fitch. On their recent analyst call, CMED claimed that they have access to other sources of funds such as commercial banks in China to provide liquidity. Based on my conversion with some analysts spoke to company earlier, the company told them it’s very hard to get the funding in current tighten credit environment locally. I am surprised that they changed their tone so easily only after two months. Also note CMED doesn’t have any valuable fixed assets as collateral.

Recommendations: Strong Sell.

   Reply  |  Private Reply
Related Stocks
Post Type